POINT Biopharma Global (PNT) 10-Q 13 Aug 21 2021 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2021	Aug. 09, 2021
Document and Entity Information [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Entity File Number	001-39311
Entity Registrant Name	POINT Biopharma Global Inc
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-0800493
Entity Address, Address Line One	4850 West 78th Street
Entity Address, City or Town	Indianapolis
Entity Address State Or Province	IN
Entity Address, Postal Zip Code	46268
City Area Code	647
Local Phone Number	812-2417
Title of 12(b) Security	Common Stock
Trading Symbol	PNT
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		90,121,794
Entity Central Index Key	0001811764
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Amendment Flag	false

Interim Condensed Consolidated

Interim Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 273,736,820	$ 10,546,749
Prepaid expenses and other current assets	8,071,586	1,850,346
Total current assets	281,808,406	12,397,095
Property, plant and equipment	15,654,223	9,797,400
Total assets	297,462,629	22,194,495
Current Liabilities
Accounts payable	5,018,089	3,596,634
Accrued liabilities	3,145,807	1,479,041
Income taxes payable	189,370	87,882
Mortgage payable, net of debt discount	3,556,322
Total current liabilities	11,909,588	5,163,557
Deferred tax liability	62,719
Mortgage payable, net of debt discount		3,550,660
Total liabilities	11,972,307	8,714,217
Commitment and contingencies (note 10)
Stockholders' equity
Common stock, par value $0.0001 per share, 430,000,000 authorized, 90,121,794 and 54,647,656 issued and outstanding as at June 30, 2021 and December 31, 2020, respectively	9,012	5,465
Additional paid-in capital	313,452,616	26,857,040
Accumulated deficit	(27,971,306)	(13,382,227)
Total stockholders' equity	285,490,322	13,480,278
Total liabilities and stockholders' equity	$ 297,462,629	$ 22,194,495

Interim Condensed Consolidate_2

Interim Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2021	Mar. 15, 2021	Dec. 31, 2020
Interim Condensed Consolidated Balance Sheets
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.001	$ 0.0001
Common Stock, Shares Authorized	430,000,000		430,000,000
Common Stock, Shares, Issued	90,121,794		54,647,656
Common Stock, Shares, Outstanding	90,121,794		54,647,656

Unaudited Interim Condensed Con

Unaudited Interim Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Operating expenses
Research and development	$ 6,700,862	$ 2,159,322	$ 10,970,160	$ 2,544,916
General and administrative	1,949,552	1,067,333	3,414,244	2,090,997
Total operating expenses	8,650,414	3,226,655	14,384,404	4,635,913
Loss from operations	(8,650,414)	(3,226,655)	(14,384,404)	(4,635,913)
Other expenses (income)
Finance costs	(2,863)		(5,662)
Foreign currency (loss) gain	(27,599)	92,919	(34,806)	(65,413)
Total other expenses (income)	(30,462)	92,919	(40,468)	(65,413)
Loss before provision for income taxes	(8,680,876)	(3,133,736)	(14,424,872)	(4,701,326)
Provision for income taxes	(123,782)	(58,261)	(164,207)	(73,505)
Net loss	$ (8,804,658)	$ (3,191,997)	$ (14,589,079)	$ (4,774,831)
Net loss per basic and diluted common share:
Basic and diluted net loss per common share	$ (0.15)	$ (0.07)	$ (0.26)	$ (0.21)
Basic and diluted weighted average common shares outstanding	57,582,025	45,362,014	57,116,747	22,986,636

Unaudited Interim Condensed C_2

Unaudited Interim Condensed Consolidated Statements of Shareholders' Equity - USD ($)	Common SharesPOINT Biopharma Inc	Common Shares	Additional Paid-in Capital	Accumulated Deficit	POINT Biopharma Inc	Total
Retroactive application of the recapitalization due to the Business Combination (refer to Note 3)	$ 0	$ 0	$ 0	$ 0		$ 0
Balance at December 31, as previously reported	0	0	0	(9,224)		(9,224)
Beginning balance at Dec. 31, 2019	0	0	0	(9,224)		(9,224)
Issuance of shares of Common Stock		$ 2,271	3,242,162	0		3,244,433
Issuance of shares of Common Stock (in shares)		22,710,246
Stock-based compensation	0	$ 0	660,163	0		660,163
Net loss	0	0	0	(1,582,834)		(1,582,834)
Ending balance at Mar. 31, 2020		$ 2,271	3,902,325	(1,592,058)		2,312,538
Ending balance (in shares) at Mar. 31, 2020		22,710,246
Beginning balance at Dec. 31, 2019	0	$ 0	0	(9,224)		(9,224)
Net loss						(4,774,831)
Ending balance at Jun. 30, 2020		$ 7,514	12,461,291	(4,784,055)		7,684,750
Ending balance (in shares) at Jun. 30, 2020		75,145,006
Beginning balance at Dec. 31, 2019	$ 0	$ 0	0	(9,224)		(9,224)
Retroactive application of the recapitalization due to the Business Combination (refer to Note 3) (in shares)	(15,233,884)	54,647,656
Balance at December 31, effect of the Business Combination (refer to Note 3) (in shares)		54,647,656
Ending balance at Dec. 31, 2020	$ 0	$ 5,465	26,857,040	(13,382,227)		$ 13,480,278
Ending balance (in shares) at Dec. 31, 2020	15,233,884					54,647,656
Beginning balance at Mar. 31, 2020		$ 2,271	3,902,325	(1,592,058)		$ 2,312,538
Beginning balance (in shares) at Mar. 31, 2020		22,710,246
Issuance of shares of Common Stock		$ 5,243	8,004,078	0		8,009,321
Issuance of shares of Common Stock (in shares)		52,434,760
Stock-based compensation	$ 0	$ 0	554,888	0		554,888
Net loss	0	0	0	(3,191,997)		(3,191,997)
Ending balance at Jun. 30, 2020		$ 7,514	12,461,291	(4,784,055)		7,684,750
Ending balance (in shares) at Jun. 30, 2020		75,145,006
Retroactive application of the recapitalization due to the Business Combination (refer to Note 3)	(15,234)	$ 5,465	9,769	0		0
Balance at December 31, as previously reported	15,234		26,847,271	(13,382,227)		13,480,278
Beginning balance at Dec. 31, 2020	$ 0	5,465	26,857,040	(13,382,227)		$ 13,480,278
Beginning balance (in shares) at Dec. 31, 2020	15,233,884					54,647,656
Issuance of shares of Common Stock in connection with exercise of warrants	$ 0	$ 287	19,999,713	0		$ 20,000,000
Issuance of shares of Common Stock in connection with exercise of warrants (in shares)		2,869,799
Issuance of shares of Common Stock in connection with stock option exercises	0	$ 6	449,994	0		450,000
Issuance of shares of Common Stock in connection with stock option exercises (in shares)		64,570
Stock-based compensation	0	$ 0	477,245	0		477,245
Net loss	0	0	0	(5,784,421)		(5,784,421)
Ending balance at Mar. 31, 2021	$ 0	$ 5,758	47,783,992	(19,166,648)		28,623,102
Ending balance (in shares) at Mar. 31, 2021	0	57,582,025
Beginning balance at Dec. 31, 2020	$ 0	$ 5,465	26,857,040	(13,382,227)		$ 13,480,278
Beginning balance (in shares) at Dec. 31, 2020	15,233,884					54,647,656
Issuance of shares of Common Stock in connection with stock option exercises (in shares)		64,570
Net loss						$ (14,589,079)
Ending balance at Jun. 30, 2021	$ 0	$ 9,012	313,452,616	(27,971,306)		$ 285,490,322
Ending balance (in shares) at Jun. 30, 2021	0	90,121,794			90,121,794	90,121,794
Beginning balance at Mar. 31, 2021	$ 0	$ 5,758	47,783,992	(19,166,648)		$ 28,623,102
Beginning balance (in shares) at Mar. 31, 2021	0	57,582,025
Issuance of shares of Common Stock, net of direct and incremental costs in connection with the Business Combination (refer to Note 3)	$ 0	$ 3,254	264,562,167	0		264,565,421
Issuance of shares of Common Stock, net of direct and incremental costs in connection with the Business Combination (refer to Note 3) (in shares)		32,539,769
Stock-based compensation	0	$ 0	1,106,457	0		1,106,457
Net loss	0	0	0	(8,804,658)		(8,804,658)
Ending balance at Jun. 30, 2021	$ 0	$ 9,012	$ 313,452,616	$ (27,971,306)		$ 285,490,322
Ending balance (in shares) at Jun. 30, 2021	0	90,121,794			90,121,794	90,121,794

Unaudited Interim Condensed C_3

Unaudited Interim Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities
Net loss		$ (14,589,079)	$ (4,774,831)
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for income taxes	$ 123,782	164,207	73,505
Stock-based compensation expense		1,583,702	1,215,051
Finance costs	2,863	5,662
Changes in operating assets and liabilities
Prepaid expenses and other current assets		(6,221,240)	(1,473,921)
Accounts payable		1,043,073	271,388
Accrued liabilities		1,149,742	331,159
Amount due to related party within accrued liabilities		33,910	150,291
Net cash used in operating activities		(16,830,023)	(4,207,358)
Cash flows from investing activities
Purchase of property, plant and equipment		(5,856,823)
Net cash used in investing activities		(5,856,823)
Cash flows from financing activities
Issuance of shares of Common Stock in connection with exercise of warrants		20,000,000
Issuance of shares of Common Stock in connection with stock option exercises		450,000	11,253,754
Issuance of shares of Common Stock in connection with the Business Combination (see note 3), net of costs incurred by RACA and direct and incremental costs paid		265,426,917
Net cash provided by financing activities		285,876,917	11,253,754
Net increase in cash and cash equivalents		263,190,071	7,046,396
Cash and cash equivalents, beginning of period		10,546,749
Cash and cash equivalents, end of period	$ 273,736,820	$ 273,736,820	$ 7,046,396

Nature of business

Nature of business	6 Months Ended
	Jun. 30, 2021
Nature of business
Nature of business	1. Nature of business Formation and organization POINT Biopharma Global Inc., together with its consolidated subsidiaries (“POINT”or the “Company”), is a late-stage clinical precision oncology company focused on the development and commercialization of next-generation radiopharmaceuticals for the treatment of cancer. On September 18, 2019, POINT Theranostics Inc. was incorporated under the General Corporation Law of the State of Delaware and amended its name to “POINT Biopharma Inc.” on November 22, 2019. On June 30, 2021, following the Business Combination (as defined below), POINT Biopharma Inc. became a wholly-owned subsidiary of POINT Biopharma Global Inc. Under the terms of the Business Combination Agreement (as defined below), shareholders of the POINT Biopharma Inc. received approximately 3.59 shares of common stock, par value $0.0001 per share, of the Company (“Common Stock”) in exchange for each common share of Point Biopharma Inc. Also in connection with the closing of the Business Combination, RACA, as defined below, consummated the sale of an aggregate of 16,500,000 shares of Class A common stock, par value $0.0001 per share, of RACA (“Class A Common Stock”) in a private placement at a price of $10.00 per share, for aggregate gross proceeds of $165,000,000 (“PIPE Financing”). In accordance with the terms of the Business Combination Agreement, upon the closing of the Business Combination, each share of Class A Common Stock and each share of Class B common stock, par value $0.0001 per share, of RACA (“Class B Common Stock”) was converted into one share of Common Stock of the Company. For additional information on the Business Combination, please see Note 3. The Company was founded on a mission to make radioligand therapy applicable to more cancers and available to more people, thereby improving the lives of cancer patients and their families everywhere. The Company has four wholly-owned subsidiaries, POINT Biopharma Inc., POINT Biopharma USA Inc. and West 78 th th

Summary of significant accounti

Summary of significant accounting policies	6 Months Ended
	Jun. 30, 2021
Summary of significant accounting policies
Summary of significant accounting policies	2. Summary of significant accounting policies Basis of presentation The accompanying unaudited interim condensed unaudited condensed financial statements have been prepared in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 270, Interim Reporting th Going Concern The Company assesses and determines its ability to continue as a going concern in accordance with the provisions of ASC Topic 205-40, Presentation of Financial Statements—Going Concern. The previously disclosed substantial doubt was alleviated following the consummation of the Business Combination. Management concluded that there are no conditions or events, in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the date of issuance of these unaudited interim condensed consolidated financial statements. The Company expects that its cash and equivalents of approximately million as of June 30, 2021, are sufficient to fund its operating expenses and capital expenditure requirements into 2024. This evaluation is based on relevant conditions and events that are known and reasonably knowable at the date of issuance of these unaudited interim condensed consolidated financial statements, including: a. The Company’s current financial condition, including its sources of liquidity; b. The Company’s conditional and unconditional obligations due or anticipated within one year; c. The funds necessary to maintain the Company’s operations considering its current financial condition, obligations, and other expected cash flows; and d. Other conditions and events, when considered in conjunction with the above, that may adversely affect the Company’s ability to meet its obligations. These unaudited interim condensed consolidated financial statements and accompanying notes have been prepared on the basis that the Company will continue as a going concern, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities. Impact of COVID-19 The COVID-19 pandemic, which was declared by the World Health Organization as a pandemic in March 2020 and has spread worldwide, has caused many governments to implement measures to slow the spread of the outbreak through quarantines, travel restrictions, heightened border security and other measures. The impact of this pandemic has been, and will likely continue to be, extensive in many aspects of society, which has resulted, and will likely continue to result, in significant disruptions to the global economy as well as businesses and capital markets around the world. The future progression of the pandemic and its effects on the Company’s business and operations are uncertain. In response to public health directives and orders and to help minimize the risk of the virus to employees, the Company has taken precautionary measures, including implementing work-from-home policies for certain employees. The impact of the virus, including work-from-home policies, may negatively impact productivity, disrupt the Company’s business, and delay its preclinical research and clinical trial activities and its development program timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on the Company’s ability to conduct its business in the ordinary course. Specifically, the Company may not be able to enroll additional patient cohorts on its planned timeline due to disruptions at its clinical trial sites. The Company is currently unable to predict when it will be able to resume normal clinical activities for its clinical programs. Other impacts to the Company’s business may include temporary closures of its suppliers and disruptions or restrictions on its employees’ ability to travel. Any prolonged material disruption to the Company’s employees or suppliers could adversely impact the Company’s preclinical research and clinical trial activities, financial condition and results of operations, including its ability to obtain financing. The Company is monitoring the ongoing impact of the COVID-19 pandemic on its business and the unaudited interim condensed consolidated financial statements. To date, the Company has not experienced any material business disruptions or incurred any impairment losses in the carrying values of its assets as a result of the pandemic, and it is not aware of any specific related event or circumstance that would require it to revise its estimates reflected in these unaudited interim condensed consolidated financial statements. Risks and uncertainties The Company has incurred significant net losses since inception and, prior to the Business Combination, has funded operations through equity financings. Operating losses and negative cash flows are expected to continue for the foreseeable future. As losses continue to be incurred, the Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, successful discovery and development of its product candidates, regulatory approval of its product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, protection of proprietary technology, compliance with governmental regulations, the impact of the COVID-19 coronavirus, the ability to secure additional capital to fund operations and commercial success of its product candidates. Product candidates currently under development will require extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. Use of estimates The preparation of the unaudited interim condensed consolidated financial statements requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, related disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements, and the reported amounts of expenses for the periods presented. Significant estimates and assumptions reflected in these unaudited interim condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuations of stock options and warrants. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. Recent accounting pronouncements not yet effective Debt with Conversion and Other Options The FASB has issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options The FASB has issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40).

Business Combination

Business Combination	6 Months Ended
	Jun. 30, 2021
Business Combination
Business Combination	3. Business Combination On March 15, 2021, POINT Biopharma Inc. entered into a definitive business combination agreement (the “Business Combination Agreement”) with Therapeutics Acquisition Corp., d/b/a Research Alliance Corp. I (“RACA”), a special purpose acquisition company, sponsored by RA Capital Management, that was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. On June 30, 2021, (the “Closing Date”), Bodhi Merger Sub, Inc. (“Bodhi Merger Sub”), a wholly-owned subsidiary of RACA’, merged with and into POINT Biopharma Inc. (the “Business Combination”), with POINT Biopharma Inc. as the surviving company in the Business Combination and, after giving effect to such Business Combination, POINT Biopharma Inc. became a wholly-owned subsidiary of RACA. RACA was then renamed “POINT Biopharma Global Inc.” In accordance with the terms of the Business Combination Agreement, upon the closing of the Business Combination: (i) each share and vested equity award of POINT Biopharma Inc. outstanding as of immediately prior to the Closing Date was converted into shares of Common Stock of the Company or comparable vested equity awards that are exercisable for shares of Common Stock of the Company, based on an implied vested equity value of $585,000,000 (which is equal to a conversion ratio of approximately 3.59 -for-1); and (ii) all unvested equity awards of POINT Biopharma Inc. were converted into comparable equity awards that are exercisable for shares of Common Stock of the Company, determined based on the same conversion ratio at which the vested equity awards are converted into shares of Common Stock of the Company; and (iii) each share of RACA Class A Common Stock and each share of RACA Class B Common Stock that was issued and outstanding immediately prior to the Closing Date became one share of Common Stock of the Company. In connection with the Business Combination, the Company consummated the PIPE Financing, pursuant to which it received $165.0 million in exchange for 16,500,000 shares of Common Stock of the Company. After giving effect to the Business Combination, there were 90,121,794 shares of Common Stock issued and outstanding We accounted for the Business Combination as a reverse recapitalization, in accordance with GAAP. POINT Biopharma Inc. is treated as the accounting acquirer (legal acquiree), while RACA is the accounting acquiree (legal acquirer) for financial reporting purposes. This determination is primarily based on the fact that the former POINT Biopharma Inc. shareholders retained a majority of the voting power of the Company and comprise a majority of the governing body of the Company, and the former assets In connection with the Business Combination, the Company incurred underwriting fees and other costs considered to be direct or incremental to the proceeds raised in connection with the Business Combination and PIPE Financing totaling approximately $22.2 million, consisting of costs incurred by RACA prior to the completion of the Business Combination as well as investment banker, legal, audit, tax, accounting and listing fees. These amounts are reflected within additional paid-in capital in the interim condensed consolidated balance sheet as of June 30, 2021. Summary of net proceeds The following table summarizes the elements of the net proceeds from the Business Combination as of June 30, 2021: ​ ​ ​ ​ ​ Recapitalization Cash - RACA Trust and cash (net of redemptions) 121,770,367 Cash - PIPE Financing 165,000,000 Less: Underwriting fees, costs incurred by RACA and other direct and incremental costs, each paid prior to June 30, 2021 (21,343,450) Proceeds from the Business Combination, net of costs incurred by RACA and direct and incremental costs paid per the statement of cash flows 265,426,917 Less: Costs incurred by RACA and direct and incremental costs, each included in accounts payable and accrued liabilities (861,496) Net proceeds from the Business Combination 264,565,421 ​ The net proceeds noted above exclude approximately $4.7 million in transaction costs that were not considered direct and incremental to the raising of capital. These costs consist of corporate expenses in the normal course of business comprised of accounting, consulting, insurance and board retainer fees. These costs were recorded as incurred in accordance with the nature of the services received. Summary of shares of Common Stock issued The following table summarizes the number of shares of Common Stock outstanding immediately following the consummation of the Business Combination: ​ ​ ​ ​ ​ Number of ​ Shares RACA Class A and Class B shares outstanding prior to the Business Combination 16,039,769 Class A shares issued pursuant to the PIPE Financing 16,500,000 Business Combination and PIPE Financing shares as converted into Common Stock 32,539,769 Conversion of POINT Biopharma Inc. common shares into Common Stock 57,582,025 Total shares of POINT Biopharma Global Inc. Common Stock outstanding immediately following the Business Combination 90,121,794 ​

Prepaid expenses and other curr

Prepaid expenses and other current assets	6 Months Ended
	Jun. 30, 2021
Prepaid expenses and other current assets
Prepaid expenses and other current assets	4. Prepaid expenses and other current assets Prepaid expenses and other current assets consisted of the following: ​ ​ ​ ​ ​ ​ ​ As of June 30, 2021 As of December 31, 2020 ​ $ $ Prepaid clinical trial expenses ​ 3,402,417 1,763,731 Deposit on production equipment ​ 592,622 — Canadian harmonized sales tax receivable ​ 31,487 58,982 Insurance ​ 3,980,461 ​ — Other ​ 64,599 27,633 Total ​ 8,071,586 1,850,346 ​

Accrued expenses

Accrued expenses	6 Months Ended
	Jun. 30, 2021
Accrued expenses
Accrued expenses	5. Accrued expenses Accrued liabilities consisted of the following: ​ ​ ​ ​ ​ ​ ​ As of June 30, 2021 As of December 31, 2020 ​ ​ $ $ Accrued financing costs ​ 489,219 ​ — Accrued research and development costs ​ 827,095 ​ 597,994 Accrued personnel costs ​ 1,381,644 ​ 540,292 Accrued corporate legal fees and other professional services ​ 280,092 ​ 210,099 Other accrued costs ​ 167,757 ​ 130,656 Total ​ 3,145,807 ​ 1,479,041 ​

Property, plant and equipment,

Property, plant and equipment, net	6 Months Ended
	Jun. 30, 2021
Property, plant and equipment, net
Property, plant and equipment, net	6. Property, plant and equipment, net Property, plant and equipment, net consisted of the following: ​ ​ ​ ​ ​ ​ ​ As of June 30, 2021 As of December 31, 2020 ​ ​ $ $ Property in development ​ 14,835,081 9,797,400 Machinery and equipment ​ 701,883 — Computer equipment ​ 95,979 — Furniture and fixtures ​ 21,280 — Total ​ 15,654,223 9,797,400 ​

Mortgage payable

Mortgage payable	6 Months Ended
	Jun. 30, 2021
Mortgage payable
Mortgage payable	7. Mortgage payable On July 10, 2020, the Company obtained a mortgage loan in the amount of $3,562,500 (the “Mortgage”) for the purpose of purchasing land and a 77,000 square-foot building located in Indianapolis, Indiana (the “Property”). The Mortgage is collateralized by a first charge over the Property. As part of the financing the Company incurred $17,194 of costs and fees from the lender that are capitalized and recorded as finance costs over the life of the Mortgage. The Mortgage bears interest at 2.85% plus a minimum rate of 1-month LIBOR, subject to a LIBOR floor of 0.25%. The Mortgage requires quarterly interest payments, which commenced on October 1, 2020, with the principal amount due at maturity on January 10, 2022. For the six months ended June 30, 2021, the Company recorded $54,605 in interest costs (June 30, 2020 — $nil) which have been capitalized within property, in development, and the Company recorded $5,662 in amortization of debt issuance costs (June 30, 2020 — $nil) through finance costs. The Mortgage is guaranteed by a stockholder of the Company (the “Guarantor”). As of June 30, 2021, the Guarantor was in compliance with this covenant. See Note 14 regarding the repayment and release of the Mortgage.

Shareholders' equity

Shareholders' equity	6 Months Ended
	Jun. 30, 2021
Shareholders' equity
Shareholders' equity	8. Stockholders’ equity Common Stock The Company is authorized to issue 430,000,000 shares of Common Stock, with a par value of $0.0001 per share,as well as 20,000,000 of shares of preferred stock, with a par value of $0.0001 per share (“Preferred Stock”). During the six months ended June 30, 2021, the Company issued 2,934,369 shares of Common Stock of which 2,869,799 shares were issued in connection with the exercise of warrants and 64,570 shares were issued in connection with the exercise of stock options issued to a non-employee consultant, each at an exercise price of $6.97 per share resulting in total cash proceeds of $20,450,000 . As of June 30, 2021, the number of total issued and outstanding December 31, 2020 issued outstanding Each share of Common Stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to receive dividends, if any, as may be declared by the Company’s board of directors. During the six months ended June 30, 2021, no cash dividends had been declared or paid by the Company (June 30, 2020 — $nil). The Company’s board of directors has the authority to issue shares of Preferred Stock from time to time on terms it may determine, to divide shares of Preferred Stock into one or more series and to fix the designations, preferences, privileges, and restrictions of Preferred Stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference, sinking fund terms, and the number of shares constituting any series or the designation of any series to the fullest extent permitted by the Delaware General Corporation Law. During the six months ended June 20, 2021, no shares of Preferred Stock have been issued by the Company (June 30, 2020 - $nil).

Share-based compensation

Share-based compensation	6 Months Ended
	Jun. 30, 2021
Share-based compensation
Share-based compensation	9. Stock-based compensation In March 2020, the board of directors of POINT Biopharma Inc. approved the 2020 Equity Incentive Plan (the “2020 EIP”). The 2020 EIP provided for the granting of incentive and nonqualified stock options, stock appreciation rights, restricted stock units, performance awards and other stock-based awards to employees, directors, and consultants of POINT Biopharma Inc. Effective as of June 30, 2021, in connection with the Business Combination, the Company’s board of directors adopted the POINT Biopharma Global Inc. 2021 Equity Incentive Plan (the “2021 EIP”) to replace the 2020 EIP and allow the Company to grant equity and equity-based incentive awards to officers, employees, non-employee directors and consultants of the Company. Upon the closing of the Business Combination, the Company assumed the outstanding equity awards under the 2020 EIP and each outstanding option to acquire common shares of Point Biopharma Inc. (whether vested or unvested) under the 2020 EIP was substituted with a substantially equivalent option to acquire shares of Common Stock of the Company based on the conversion ratio for the POINT Biopharma Inc. common shares in the Business Combination and remains outstanding under the 2020 EIP. No further grants may be made under the 2020 EIP. The Company concluded that the replacement stock options issued in connection with the Business Combination did not require accounting for effects of the modification under the ASC 718 – Compensation – Stock Compensation The Company recorded $1,028,512 to research and development expense and $77,945 to general and administrative expenses for stock-based compensation for the three months ended June 30, 2021 (June 30, 2020 — $554,888 to general and administrative expenses). The Company recorded $1,428,669 to research and development expense and $155,033 to general and administrative expenses for stock-based compensation for the six months ended June 30, 2021 (June 30, 2020 - $1,215,051 to general and administrative expenses). The Company did not recognize a tax benefit related to stock-based compensation expense during the six months ended June 30, 2021, as the Company had net operating losses carryforwards and recorded a valuation allowance against the deferred tax asset. The following table summarizes the activity relating to the Company’s stock options. The below stock option figures are presented giving effect to a retroactive application of the Business Combination which resulted in a replacement of the previous Point Biopharma Inc. stock options with stock options of the Company, as described above, at a conversion ratio of approximately 3.59:1. In addition, the exercise price for each replacement stock option is also adjusted at using the ratio of approximately 3.59:1. See Note 3 for additional details: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ Weighted ​ Remaining ​ ​ Number of ​ Average Exercise ​ Contractual ​ Shares Price Term (in years) Outstanding as of December 31, 2020 2,364,010 2.88 ​ Granted 358,724 6.97 ​ Exercised (64,570) 6.97 ​ Forfeited (35,872) 6.97 ​ Outstanding as of June 30, 2021 2,622,292 3.28 5.5 Vested and expected to vest as of June 30, 2021 2,622,292 3.28 5.5 Options exercisable as of June 30, 2021 917,885 4.34 6.6 ​ During the three months ended June 30, 2021, no stock options were granted. During the six months ended June 30, 2021, 358,724 stock options, were granted to a non-employee consultant of the Company. The vesting terms of the grant are such that 25% of the options vested immediately upon grant, 10% of the options were initially to vest in a year following the grant and the remaining During the three months ended June 30, 2020, no stock options were granted. During the six months ended June 30, 2020, 6,787 stock options were granted to an employee and 1,727,666 stock options were granted to non-employee consultants of the Company. The vesting terms of these grants are such that 25% of the options vest after the 1 st year anniversary of the date of grant and the remaining options vesting ratably over the remaining three years . The following table presents the assumptions used in the Black-Scholes-Merton option-pricing model to determine the grant date fair value of stock options granted: ​ ​ ​ ​ ​ ​ ​ ​ Six months ended Six months ended ​ June 30, 2021 ​ June 30, 2020 Risk-free interest rate 0.716 % 0.504 % Expected term (in years) 5.375 4.25 ​ Expected volatility 65 % 65 % Expected dividend yield 0 % 0 % ​ During the six months ended June 30, 2021, a non-employee consultant of the Company exercised 64,570 stock options resulting in the issuance of 64,570 shares of Common Stock for cash proceeds of $450,000. As of June 30, 2021, the unrecognized stock-based compensation expense related to unvested stock options, was $1,118,674 and the estimated weighted average remaining vesting period was 2.3 years.

Commitments and contingencies

Commitments and contingencies	6 Months Ended
	Jun. 30, 2021
Commitments and contingencies.
Commitments and contingencies	10. Commitments and contingencies Property, in development commitment The Company entered into agreements for the engineering design and modification of the property, in development. As at June 30, 2021, the Company is committed to future payments of approximately $4.6 million, relating to the construction and retrofit of the building, which are due before the expected completion in fiscal year 2021. During the three and six months ended June 30, 2021, approximately $2.2 million and $4.9 million, respectively has been recorded within property, plant and equipment in connection with these agreements (three and six months ended June 30, 2020 – $0.1 million and $0.1 million, respectively). Clinical trial and commercial commitments The Company in the normal course of business enters into various services and supply agreements in connection with its clinical trials to ensure the supply of certain product and product lines during the Company’s clinical phase. These agreements often have minimal purchase commitments and generally terminate upon the termination of the clinical trial. Minimum purchase commitments under these agreements range from $200,000 to $3,200,000 with a total aggregate remaining minimum commitment amount of approximately $8.0 million with payments ranging from three The Company also has a supply agreement with a third party to purchase certain products for use in the Company’s full scale production process. The Company is committed to purchase a minimum quantity of product in the amount of approximately $50.7 million ($62.9 million CAD) over the contract term. The purchase commitments are contingent upon the completion of certain milestones by the third-party supplier. The Company recorded $nil and $nil, respectively, in connection with this agreement during the three and six months ended June 30, 2021 (three and six months ended June 30, 2020 - $nil and $nil, respectively). The Company also has an agreement with a third party to provide certain services in connection with the Company’s SPLASH clinical phase study. The agreement expires on the date of the completion or termination of the clinical trial. The remaining minimum purchase commitment under this agreement is approximately $51.3 million with payments that range from one License agreements The Company in the normal course of business enters into license and sublicense agreements in connection with its clinical trials and product development. For additional details of the Company’s license agreements, see Note 12 in the 2020 Financial Statements. The Company recorded research and development expenses in connection to its license agreements of approximately $0.5 million and $1.0 million, respectively, during the three and six months ended June 30, 2021 (three and six months ended June 30, 2020 – $nil and $nil, respectively). On June 30, 2021, the Company entered into a license agreement with the Belgian Nuclear Research Centre (“SCK-CEN”). Under the SCK-CEN Agreement, the Company was granted a worldwide, royalty-bearing, non-exclusive, sublicensable license under SCK-CEN’s patent rights to develop, make, have made, use and import the no-carrier added Lu-177 using SCK CEN Technology. The Company is obligated to make aggregate milestone payments to SCK-CEN of up to $130,000 (€110,000) upon the achievement of certain technology implementation milestones. The Company is also obligated to make aggregate minimum royalty payments of $8,500,000 (€7,120,000) over the course of 8 years commencing in 2023. The Company did not record any costs in connection to this license agreement as of June 30, 2021.

Net loss per share

Net loss per share	6 Months Ended
	Jun. 30, 2021
Net loss per share
Net loss per share	11. Net loss per share Basic loss earnings per share is computed by dividing the loss available to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period. Diluted loss per share is computed by dividing loss available to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive securities had been issued, using the treasury stock method. The below figures are presented giving effect to a retroactive application of the Business Combination which resulted in a conversion of the previous Point Biopharma Inc. common shares to shares of Common Stock of the Company at a conversion ratio of approximately 3.59:1. See Note 3. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ​ Three months ​ Six months ​ Six months ​ ​ ended June 30, ​ ended June 30, ​ ended June 30, ​ ended June 30, ​ 2021 2020 2021 2020 Net loss attributable to common stockholders ​ ​ 8,804,658 ​ 3,191,997 ​ ​ 14,589,079 ​ 4,774,831 Weighted-average common shares outstanding-basic and diluted ​ ​ 57,582,025 ​ 45,362,014 ​ ​ 57,116,747 ​ 22,986,636 Net loss per share attributable to common stockholders-basic and diluted ​ $ 0.15 ​ $ 0.07 ​ $ 0.26 ​ $ 0.21 ​ The Company’s potentially dilutive securities, which include stock options and warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of shares of Common Stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2021
Income Taxes
Income Taxes	12. Income Taxes The Company has operations in both the United States and Canada, as such it is subject to tax in both countries. The income tax expense for the three months ended June 30, 2021 and June 30, 2020 was $123,782 and $58,261 respectively. The income tax expense for the six months ended June 30, 2021 and June 30, 2020 was $164,207 and $73,505 respectively. As of June 30, 2021, the Company had no uncertain tax positions (December 31, 2020 — $nil). The Company files income tax returns in the US federal, certain state, and Canada with varying statutes of limitations. The Company is not currently subject to tax examinations by any taxing jurisdiction. However, in the event of any such examination of its tax years 2019 and 2020, there may or may not be an impact on the Company’s net operating loss carryforwards and credits. The Company does not anticipate that any potential tax adjustments resulting from such examinations will have a significant impact on its financial position or results of operations. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was passed into law. The CARES Act includes several significant business tax provisions including modification to the taxable income limitation for utilization of net operating losses incurred in 2019 and 2020, an increase to the limitation on deductibility of certain business interest expense, bonus depreciation for purchases of qualified improvement property and special deductions on certain corporate charitable contributions. The Company analyzed the provisions of the CARES Act and determined there was no impact to its income tax provision for the three and six months ended June 30, 2021 and 2020.

Related party transactions

Related party transactions	6 Months Ended
	Jun. 30, 2021
Related party transactions
Related party transactions	13. Related party transactions The Company recognized expenses in connection with related party transactions in the unaudited condensed consolidated statements of operations as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended ​ Three months ended ​ Six months ended ​ Six months ended ​ ​ June 30, 2021 ​ June 30, 2020 ​ June 30, 2021 ​ June 30, 2020 ​ $ $ $ $ Stock-based compensation for consulting arrangement ​ — ​ 554,888 ​ — ​ 1,109,776 Consulting fees to stockholder ​ — ​ 88,267 ​ — ​ 160,691 Consulting fees on business activities to Board member ​ 53,892 ​ 34,207 ​ 83,878 ​ 56,369 Reimbursement to Board member for occupancy costs ​ 19,584 ​ — ​ 36,819 ​ — Total ​ 73,476 ​ 677,362 ​ 120,697 ​ 1,326,836 ​ Transactions with related parties are in the normal course of operations and have been measured at their agreed upon exchange amount. During the six months ended June 30, 2020, the Company issued stock options to shareholders of a related party in exchange primarily for legal and financial consulting services. No amounts are owing in respect of these services as of June 30, 2021. During the six-month periods ended June 30, 2021 and 2020, the Company received consulting services for research and development from a Board member, for which $33,910 is recorded within accrued liabilities as of June 30, 2021. In addition, during the six months ended June 30, 2020, the Company received consulting services for manufacturing planning from a shareholder. No amounts are owing in respect of these services as of June 30, 2021. The Company currently has a lease arrangement in place with a Board member for the use of office space. The arrangement does not have a defined contractual lease term and is payable monthly. The Company has applied the short-term lease exemption under ASC Topic 842, Leases to this arrangement and is recording the lease payments of approximately $6,000 monthly as rent expense.

Subsequent events

Subsequent events	6 Months Ended
	Jun. 30, 2021
Subsequent events
Subsequent events	14. Subsequent events Issuance of stock options On July 6, 2021, the Company granted 1,004,959 stock options for the purchase of shares of Common Stock, each with an exercise price of $8.47, to its non-employee directors and certain executive officers and other employees. The vesting terms of these options are such that 25% of the options vest after the 1 st remaining Repayment of Mortgage On July 29, 2021, the Mortgage on the manufacturing facility in Indianapolis, Indiana was repaid and the related guarantee was released.

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	6 Months Ended
	Jun. 30, 2021
Summary of significant accounting policies
Basis of presentation	Basis of presentation The accompanying unaudited interim condensed unaudited condensed financial statements have been prepared in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 270, Interim Reporting th
Going concern	Going Concern The Company assesses and determines its ability to continue as a going concern in accordance with the provisions of ASC Topic 205-40, Presentation of Financial Statements—Going Concern. The previously disclosed substantial doubt was alleviated following the consummation of the Business Combination. Management concluded that there are no conditions or events, in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the date of issuance of these unaudited interim condensed consolidated financial statements. The Company expects that its cash and equivalents of approximately million as of June 30, 2021, are sufficient to fund its operating expenses and capital expenditure requirements into 2024. This evaluation is based on relevant conditions and events that are known and reasonably knowable at the date of issuance of these unaudited interim condensed consolidated financial statements, including: a. The Company’s current financial condition, including its sources of liquidity; b. The Company’s conditional and unconditional obligations due or anticipated within one year; c. The funds necessary to maintain the Company’s operations considering its current financial condition, obligations, and other expected cash flows; and d. Other conditions and events, when considered in conjunction with the above, that may adversely affect the Company’s ability to meet its obligations. These unaudited interim condensed consolidated financial statements and accompanying notes have been prepared on the basis that the Company will continue as a going concern, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities.
Impact of Covid-19	Impact of COVID-19 The COVID-19 pandemic, which was declared by the World Health Organization as a pandemic in March 2020 and has spread worldwide, has caused many governments to implement measures to slow the spread of the outbreak through quarantines, travel restrictions, heightened border security and other measures. The impact of this pandemic has been, and will likely continue to be, extensive in many aspects of society, which has resulted, and will likely continue to result, in significant disruptions to the global economy as well as businesses and capital markets around the world. The future progression of the pandemic and its effects on the Company’s business and operations are uncertain. In response to public health directives and orders and to help minimize the risk of the virus to employees, the Company has taken precautionary measures, including implementing work-from-home policies for certain employees. The impact of the virus, including work-from-home policies, may negatively impact productivity, disrupt the Company’s business, and delay its preclinical research and clinical trial activities and its development program timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on the Company’s ability to conduct its business in the ordinary course. Specifically, the Company may not be able to enroll additional patient cohorts on its planned timeline due to disruptions at its clinical trial sites. The Company is currently unable to predict when it will be able to resume normal clinical activities for its clinical programs. Other impacts to the Company’s business may include temporary closures of its suppliers and disruptions or restrictions on its employees’ ability to travel. Any prolonged material disruption to the Company’s employees or suppliers could adversely impact the Company’s preclinical research and clinical trial activities, financial condition and results of operations, including its ability to obtain financing. The Company is monitoring the ongoing impact of the COVID-19 pandemic on its business and the unaudited interim condensed consolidated financial statements. To date, the Company has not experienced any material business disruptions or incurred any impairment losses in the carrying values of its assets as a result of the pandemic, and it is not aware of any specific related event or circumstance that would require it to revise its estimates reflected in these unaudited interim condensed consolidated financial statements.
Risks and uncertainties	Risks and uncertainties The Company has incurred significant net losses since inception and, prior to the Business Combination, has funded operations through equity financings. Operating losses and negative cash flows are expected to continue for the foreseeable future. As losses continue to be incurred, the Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, successful discovery and development of its product candidates, regulatory approval of its product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, protection of proprietary technology, compliance with governmental regulations, the impact of the COVID-19 coronavirus, the ability to secure additional capital to fund operations and commercial success of its product candidates. Product candidates currently under development will require extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.
Use of estimates	Use of estimates The preparation of the unaudited interim condensed consolidated financial statements requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, related disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements, and the reported amounts of expenses for the periods presented. Significant estimates and assumptions reflected in these unaudited interim condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuations of stock options and warrants. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
Recent accounting pronouncements not yet effective	Recent accounting pronouncements not yet effective Debt with Conversion and Other Options The FASB has issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options The FASB has issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40).

Business Combination (Tables)

Business Combination (Tables)	6 Months Ended
	Jun. 30, 2021
Business Combination
Summary of net proceeds from the Business Combination	​ ​ ​ ​ ​ Recapitalization Cash - RACA Trust and cash (net of redemptions) 121,770,367 Cash - PIPE Financing 165,000,000 Less: Underwriting fees, costs incurred by RACA and other direct and incremental costs, each paid prior to June 30, 2021 (21,343,450) Proceeds from the Business Combination, net of costs incurred by RACA and direct and incremental costs paid per the statement of cash flows 265,426,917 Less: Costs incurred by RACA and direct and incremental costs, each included in accounts payable and accrued liabilities (861,496) Net proceeds from the Business Combination 264,565,421
Summary of number of shares of common stock outstanding immediately following the consummation of the Business Combination	​ ​ ​ ​ ​ Number of ​ Shares RACA Class A and Class B shares outstanding prior to the Business Combination 16,039,769 Class A shares issued pursuant to the PIPE Financing 16,500,000 Business Combination and PIPE Financing shares as converted into Common Stock 32,539,769 Conversion of POINT Biopharma Inc. common shares into Common Stock 57,582,025 Total shares of POINT Biopharma Global Inc. Common Stock outstanding immediately following the Business Combination 90,121,794

Prepaid expenses and other cu_2

Prepaid expenses and other current assets (Tables)	6 Months Ended
	Jun. 30, 2021
Prepaid expenses and other current assets
Summary of prepaid expenses and other current assets	​ ​ ​ ​ ​ ​ ​ As of June 30, 2021 As of December 31, 2020 ​ $ $ Prepaid clinical trial expenses ​ 3,402,417 1,763,731 Deposit on production equipment ​ 592,622 — Canadian harmonized sales tax receivable ​ 31,487 58,982 Insurance ​ 3,980,461 ​ — Other ​ 64,599 27,633 Total ​ 8,071,586 1,850,346

Accrued expenses (Tables)

Accrued expenses (Tables)	6 Months Ended
	Jun. 30, 2021
Accrued expenses
Summary of accrued liabilities	​ ​ ​ ​ ​ ​ ​ As of June 30, 2021 As of December 31, 2020 ​ ​ $ $ Accrued financing costs ​ 489,219 ​ — Accrued research and development costs ​ 827,095 ​ 597,994 Accrued personnel costs ​ 1,381,644 ​ 540,292 Accrued corporate legal fees and other professional services ​ 280,092 ​ 210,099 Other accrued costs ​ 167,757 ​ 130,656 Total ​ 3,145,807 ​ 1,479,041

Property, plant and equipment_2

Property, plant and equipment, net (Tables)	6 Months Ended
	Jun. 30, 2021
Property, plant and equipment, net
Summary of property, plant and equipment, net	​ ​ ​ ​ ​ ​ ​ As of June 30, 2021 As of December 31, 2020 ​ ​ $ $ Property in development ​ 14,835,081 9,797,400 Machinery and equipment ​ 701,883 — Computer equipment ​ 95,979 — Furniture and fixtures ​ 21,280 — Total ​ 15,654,223 9,797,400

Share-based compensation (Table

Share-based compensation (Tables)	6 Months Ended
	Jun. 30, 2021
Share-based compensation
Summary of stock option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ Weighted ​ Remaining ​ ​ Number of ​ Average Exercise ​ Contractual ​ Shares Price Term (in years) Outstanding as of December 31, 2020 2,364,010 2.88 ​ Granted 358,724 6.97 ​ Exercised (64,570) 6.97 ​ Forfeited (35,872) 6.97 ​ Outstanding as of June 30, 2021 2,622,292 3.28 5.5 Vested and expected to vest as of June 30, 2021 2,622,292 3.28 5.5 Options exercisable as of June 30, 2021 917,885 4.34 6.6 ​
Summary of assumptions used in the Black-Scholes-Merton option-pricing model to determine the grant date fair value of stock options granted	​ ​ ​ ​ ​ ​ ​ ​ Six months ended Six months ended ​ June 30, 2021 ​ June 30, 2020 Risk-free interest rate 0.716 % 0.504 % Expected term (in years) 5.375 4.25 ​ Expected volatility 65 % 65 % Expected dividend yield 0 % 0 %

Net loss per share (Tables)

Net loss per share (Tables)	6 Months Ended
	Jun. 30, 2021
Net loss per share
Summary of basic and diluted net loss per share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ​ Three months ​ Six months ​ Six months ​ ​ ended June 30, ​ ended June 30, ​ ended June 30, ​ ended June 30, ​ 2021 2020 2021 2020 Net loss attributable to common stockholders ​ ​ 8,804,658 ​ 3,191,997 ​ ​ 14,589,079 ​ 4,774,831 Weighted-average common shares outstanding-basic and diluted ​ ​ 57,582,025 ​ 45,362,014 ​ ​ 57,116,747 ​ 22,986,636 Net loss per share attributable to common stockholders-basic and diluted ​ $ 0.15 ​ $ 0.07 ​ $ 0.26 ​ $ 0.21

Related party transaction (Tabl

Related party transaction (Tables)	6 Months Ended
	Jun. 30, 2021
Related party transactions
Schedule of related party transactions	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended ​ Three months ended ​ Six months ended ​ Six months ended ​ ​ June 30, 2021 ​ June 30, 2020 ​ June 30, 2021 ​ June 30, 2020 ​ $ $ $ $ Stock-based compensation for consulting arrangement ​ — ​ 554,888 ​ — ​ 1,109,776 Consulting fees to stockholder ​ — ​ 88,267 ​ — ​ 160,691 Consulting fees on business activities to Board member ​ 53,892 ​ 34,207 ​ 83,878 ​ 56,369 Reimbursement to Board member for occupancy costs ​ 19,584 ​ — ​ 36,819 ​ — Total ​ 73,476 ​ 677,362 ​ 120,697 ​ 1,326,836

Nature of business (Details)

Nature of business (Details)	Jun. 30, 2021USD ($)$ / sharesshares	Nov. 22, 2019subsidiary
Nature Of Business [Line Items]
Exchange for each common share | shares	3.59
Exchange of common stock per share	$ 0.0001
Number of wholly-owned subsidiaries | subsidiary		4
Price per share	$ 6.97
Private Placement
Nature Of Business [Line Items]
PIPE financing | $	$ 165,000,000
Private placement at a price	$ 10
Class B common shares
Nature Of Business [Line Items]
Price per share	$ 0.0001
RACA | Class A common shares
Nature Of Business [Line Items]
Sale of aggregate shares | shares	16,500,000
Price per share	$ 0.0001

Summary of significant accoun_3

Summary of significant accounting policies (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Going concern
Cash and cash equivalents	$ 273,736,820	$ 10,546,749

Business Combination (Details)

Business Combination (Details)	Jun. 30, 2021USD ($)shares	Jun. 30, 2021USD ($)itemshares	Dec. 31, 2020shares
Business Acquisition [Line Items]
Exchange ratio	3.59	3.59
Common stock issued | shares	90,121,794	90,121,794	54,647,656
Common stock outstanding | shares	90,121,794	90,121,794	54,647,656
Number of common share of the company | item		1
Net proceeds excluding transaction costs	$ 4,700,000
POINT Biopharma Inc
Business Acquisition [Line Items]
Implied vested equity value	$ 585,000,000	$ 585,000,000
Number of common shares received for each share | shares	16,500,000	16,500,000
PIPE Financing	$ 165,000,000	$ 165,000,000
Common stock outstanding | shares	90,121,794	90,121,794
Goodwill	$ 0	$ 0
Other intangible assets	$ 0	0
Business Combination, Acquisition Related Costs		$ 22,200,000

Business Combination - Summary

Business Combination - Summary of Net proceeds (Details) - POINT Biopharma Inc	6 Months Ended
	Jun. 30, 2021USD ($)
Business Acquisition [Line Items]
Cash - RACA Trust and cash (net of redemptions)	$ 121,770,367
Cash - PIPE Financing	165,000,000
Less: Underwriting fees, costs incurred by RACA and other direct and incremental costs, each paid prior to June 30, 2021	(21,343,450)
Proceeds from the Business Combination, net of costs incurred by RACA and direct and incremental costs paid per the statement of cash flows	265,426,917
Less: Costs incurred by RACA and direct and incremental costs, each included in accounts payable and accrued liabilities	(861,496)
Net proceeds from the Business Combination	$ 264,565,421

Business Combination - Summar_2

Business Combination - Summary of Shares of Common Stock Issued (Details) - shares	Jun. 30, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Total shares of POINT Biopharma Global Inc. Common Stock outstanding immediately following the Business Combination	90,121,794	54,647,656
POINT Biopharma Inc
Business Acquisition [Line Items]
RACA Class A and Class B shares outstanding prior to the Business Combination	16,039,769
Class A shares issued pursuant to the PIPE Financing	16,500,000
Business Combination and PIPE Financing shares as converted into Common Stock	32,539,769
Conversion of POINT Biopharma Inc. common shares into Common Stock	57,582,025
Total shares of POINT Biopharma Global Inc. Common Stock outstanding immediately following the Business Combination	90,121,794

Prepaid expenses and other cu_3

Prepaid expenses and other current assets (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Prepaid expenses and other current assets
Prepaid clinical trial expenses	$ 3,402,417	$ 1,763,731
Deposit on production equipment	592,622
Canadian harmonized sales tax receivable	31,487	58,982
Insurance	3,980,461
Other	64,599	27,633
Total	$ 8,071,586	$ 1,850,346

Accrued expenses (Details)

Accrued expenses (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Accrued expenses
Accrued financing costs	$ 489,219
Accrued research and development costs	827,095	$ 597,994
Accrued personnel costs	1,381,644	540,292
Accrued corporate legal fees and other professional services	280,092	210,099
Other accrued costs	167,757	130,656
Total	$ 3,145,807	$ 1,479,041

Property, plant and equipment_3

Property, plant and equipment, net (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	$ 15,654,223	$ 9,797,400
Property in development
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	14,835,081	$ 9,797,400
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	701,883
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	21,280
Computer equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	$ 95,979

Mortgage payable (Details)

Mortgage payable (Details)	Jul. 10, 2020USD ($)ft²	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)
Debt Instrument [Line Items]
Mortgage loan obtained	$ 3,562,500
Square-foot of building | ft²	77,000
Costs and fees incurred that are capitalized and recorded as finance costs over the life of the Mortgage	$ 17,194
Interest costs		$ 54,605	$ 0
Amortization of debt issuance costs		$ 5,662	$ 0
LIBOR
Debt Instrument [Line Items]
Spread on variable rate	2.85%
LIBOR floor	0.25%

Shareholders' equity (Details)

Shareholders' equity (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2020shares	Mar. 31, 2020shares	Jun. 30, 2021USD ($)Vote$ / sharesshares	Jun. 30, 2020USD ($)shares	Mar. 31, 2021shares	Mar. 15, 2021$ / shares	Dec. 31, 2020$ / sharesshares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common shares, authorized			430,000,000				430,000,000
Common shares, par value | $ / shares			$ 0.0001			$ 0.001	$ 0.0001
Price per share | $ / shares			$ 6.97
Issuance of common shares and warrants | $			$ 20,450,000
Common shares, shares issued			90,121,794				54,647,656
Common shares, shares outstanding			90,121,794				54,647,656
Number of votes per share | Vote			1
Cash dividend declared | $			$ 0
Cash dividend paid | $				$ 0
Exchange ratio			3.59
Preferred stock, shares Issued			0				0
Preferred stock, shares Outstanding			0				0
Stock options.
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued during period			64,570
Warrants
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued during period			2,869,799
Preferred shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred shares, shares authorized			20,000,000
Preferred Stock, Par or Stated Value Per Share | $ / shares			$ 0.0001
Common Shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued during period	52,434,760	22,710,246
Number of shares issued during period			2,934,369
Common shares, shares outstanding	75,145,006	22,710,246	90,121,794	75,145,006	57,582,025

Share-based compensation (Detai

Share-based compensation (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exchange ratio	3.59		3.59
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ 1,028,512		$ 1,428,669
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ 77,945	$ 554,888	$ 155,033	$ 1,215,051

Share-based compensation - Summ

Share-based compensation - Summarizes activity relating to options to purchase stock (Details) - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Weighted-Average Remaining Contractual Term (in years)
Proceeds from issuance of common shares				$ 265,426,917
Unvested stock options, vested				269,043
Common Shares
Number of Shares
Exercised		(64,570)		(64,570)
Weighted-Average Remaining Contractual Term (in years)
Issuance of shares of Common Stock in connection with stock option exercises (in shares)		64,570		64,570
Vesting immediately upon grant
Weighted-Average Remaining Contractual Term (in years)
Vesting percentage				25.00%
Vesting on 1st year anniversary
Weighted-Average Remaining Contractual Term (in years)
Vesting percentage				10.00%
Vesting based on certain performance milestones
Weighted-Average Remaining Contractual Term (in years)
Vesting percentage				75.00%
Non-employee consultant
Weighted-Average Remaining Contractual Term (in years)
Proceeds from issuance of common shares				$ 450,000
Stock options.
Number of Shares
Outstanding at the beginning		2,364,010		2,364,010
Granted				358,724
Exercised				(64,570)
Forfeited				(35,872)
Outstanding at the end	2,622,292			2,622,292
Vested and expected to vest	2,622,292			2,622,292
Options exercisable	917,885			917,885
Weighted Average Exercise Price
Outstanding at the beginning (in dollars per share)		$ 2.88		$ 2.88
Granted (in dollars per share)				6.97
Exercised (in dollars per share)				6.97
Forfeited (in dollars per share)				6.97
Outstanding at the end (in dollars per share)	$ 3.28			3.28
Vested and expected to vest (in dollars per share)	3.28			3.28
Options exercisable (in dollars per share)	$ 4.34			$ 4.34
Weighted-Average Remaining Contractual Term (in years)
Outstanding (in years)				5 years 6 months
Vested and expected to vest (in years)				5 years 6 months
Options exercisable (in years)				6 years 7 months 6 days
Number of options granted				358,724
Issuance of shares of Common Stock in connection with stock option exercises (in shares)				64,570
Stock options. | Vesting on 1st year anniversary
Weighted-Average Remaining Contractual Term (in years)
Vesting percentage					25.00%
Vesting period					3 years
Stock options. | Vesting ratably over the remaining three years
Weighted-Average Remaining Contractual Term (in years)
Vesting percentage					75.00%
Stock options. | Employee
Number of Shares
Granted			0		6,787
Weighted-Average Remaining Contractual Term (in years)
Number of options granted			0		6,787
Stock options. | Non-employee consultant
Number of Shares
Granted	0			358,724	1,727,666
Exercised				(64,570)
Weighted-Average Remaining Contractual Term (in years)
Number of options granted	0			358,724	1,727,666
Issuance of shares of Common Stock in connection with stock option exercises (in shares)				64,570

Share-based compensation - Assu

Share-based compensation - Assumptions used in Black-Scholes-Merton option-pricing model (Details)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Share-based compensation
Risk-free interest rate	0.716%	0.504%
Expected term (in years)	5 years 4 months 15 days	4 years 3 months
Expected volatility	65.00%	65.00%
Expected dividend yield	0.00%	0.00%

Share-based compensation - Unre

Share-based compensation - Unrecognized share-based compensation expense (Details)	6 Months Ended
	Jun. 30, 2021USD ($)
Share-based compensation
Unrecognized share-based compensation expense	$ 1,118,674
Unrecognized share-based compensation expense, weighted average remaining vesting period	2 years 3 months 18 days

Commitments and contingencies (

Commitments and contingencies (Details) - Property, in development commitment - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Other Commitments [Line Items]
Future payments relating to the construction and retrofit of the building	$ 4.6		$ 4.6
Total aggregate remaining minimum commitment	$ 2.2	$ 0.1	$ 4.9	$ 0.1

Commitments and contingencies -

Commitments and contingencies - Clinical trial and commercial commitments & License agreements (Details) $ in Millions	Jun. 30, 2021USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2021CAD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021EUR (€)
License agreements
Long-term Purchase Commitment [Line Items]
Aggregate milestone payments	$ 130,000	$ 130,000		$ 130,000			€ 110,000
Aggregate minimum royalty payments	$ 8,500,000	8,500,000		8,500,000			€ 7,120,000
Term of agreement	8 years
License agreements | Research and development
Long-term Purchase Commitment [Line Items]
Total aggregate remaining minimum commitment		500,000	$ 0	1,000,000		$ 0
Supply agreements in connection with clinical trials
Long-term Purchase Commitment [Line Items]
Total aggregate remaining minimum commitment				8,000,000
Supply agreements in connection with clinical trials | Minimum
Long-term Purchase Commitment [Line Items]
Minimum purchase commitments				$ 200,000
Term for total aggregate remaining minimum commitment				3 years	3 years
Supply agreements in connection with clinical trials | Maximum
Long-term Purchase Commitment [Line Items]
Minimum purchase commitments				$ 3,200,000
Term for total aggregate remaining minimum commitment				8 years	8 years
Supply agreements in connection | Research and development
Long-term Purchase Commitment [Line Items]
Total aggregate remaining minimum commitment		800,000	0	$ 1,300,000		0
Supply agreement to purchase certain products
Long-term Purchase Commitment [Line Items]
Minimum purchase commitments				50,700,000	$ 62.9
Agreement in connection with the SPLASH clinical phase study | Research and development
Long-term Purchase Commitment [Line Items]
Total aggregate remaining minimum commitment		1,800,000	200,000	3,000,000		200,000
Agreement in connection with the SPLASH clinical phase study | Minimum
Long-term Purchase Commitment [Line Items]
Total aggregate remaining minimum commitment				$ 51,300,000
Term for total aggregate remaining minimum commitment				1 year	1 year
Agreement in connection with the SPLASH clinical phase study | Maximum
Long-term Purchase Commitment [Line Items]
Term for total aggregate remaining minimum commitment				6 years	6 years
Agreement in connection
Long-term Purchase Commitment [Line Items]
Total aggregate remaining minimum commitment		$ 0	$ 0	$ 0		$ 0

Net loss per share (Details)

Net loss per share (Details)	3 Months Ended				6 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares	Mar. 31, 2021USD ($)	Jun. 30, 2020USD ($)$ / sharesshares	Mar. 31, 2020USD ($)	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2020USD ($)$ / sharesshares
Net loss per share
Net loss attributable to common stockholders | $	$ 8,804,658	$ 5,784,421	$ 3,191,997	$ 1,582,834	$ 14,589,079	$ 4,774,831
Weighted-average common shares outstanding - basic and diluted | shares	57,582,025		45,362,014		57,116,747	22,986,636
Net loss per share attributable to common stockholders - basic and diluted | $ / shares	$ 0.15		$ 0.07		$ 0.26	$ 0.21
Exchange ratio	3.59				3.59

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Income Taxes
Provision for income taxes	$ 123,782	$ 58,261	$ 164,207	$ 73,505
Uncertain tax positions	$ 0		$ 0		$ 0

Related party transactions (Det

Related party transactions (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Related Party Transaction [Line Items]
Related party expenses	$ 73,476	$ 677,362	$ 120,697	$ 1,326,836
Amount due to related party	0		0
Accrued liabilities	33,910	33,910	33,910	33,910
Rent expense with related party			6,000
Stock-based compensation for consulting arrangement
Related Party Transaction [Line Items]
Related party expenses		554,888		1,109,776
Consulting fees to stockholder
Related Party Transaction [Line Items]
Related party expenses		88,267		160,691
Consulting fees on business activities to Board member
Related Party Transaction [Line Items]
Related party expenses	53,892	$ 34,207	83,878	$ 56,369
Reimbursement to Board member for occupancy costs
Related Party Transaction [Line Items]
Related party expenses	$ 19,584		$ 36,819

Subsequent events (Details)

Subsequent events (Details) - $ / shares	Jul. 06, 2021	Jun. 30, 2021
Subsequent events. | Stock options | Non-employee directors and certain executive officers and other employees
Subsequent Event [Line Items]
Number of options granted	1,004,959
Exercise price	$ 8.47
Vesting on 1st year anniversary
Subsequent Event [Line Items]
Vesting percentage		10.00%
Vesting on 1st year anniversary | Subsequent events. | Stock options | Non-employee directors and certain executive officers and other employees
Subsequent Event [Line Items]
Vesting percentage	25.00%
Vesting ratably over the remaining three years | Subsequent events. | Stock options | Non-employee directors and certain executive officers and other employees
Subsequent Event [Line Items]
Vesting percentage	75.00%
Vesting period	3 years